Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Accumulated Expenses: 2017-2025

Historic Accumulated Expenses for Cidara Therapeutics (CDTX) over the last 9 years, with Sep 2025 value amounting to $71.3 million.

  • Cidara Therapeutics' Accumulated Expenses rose 732.64% to $71.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.3 million, marking a year-over-year increase of 732.64%. This contributed to the annual value of $13.3 million for FY2024, which is 5.85% down from last year.
  • Latest data reveals that Cidara Therapeutics reported Accumulated Expenses of $71.3 million as of Q3 2025, which was up 545.46% from $11.1 million recorded in Q2 2025.
  • Over the past 5 years, Cidara Therapeutics' Accumulated Expenses peaked at $71.3 million during Q3 2025, and registered a low of $6.2 million during Q2 2024.
  • Its 3-year average for Accumulated Expenses is $16.7 million, with a median of $11.1 million in 2025.
  • Per our database at Business Quant, Cidara Therapeutics' Accumulated Expenses crashed by 37.89% in 2024 and then skyrocketed by 732.64% in 2025.
  • Cidara Therapeutics' Accumulated Expenses (Quarterly) stood at $10.2 million in 2021, then dropped by 24.77% to $7.7 million in 2022, then surged by 84.79% to $14.2 million in 2023, then fell by 5.85% to $13.3 million in 2024, then soared by 732.64% to $71.3 million in 2025.
  • Its Accumulated Expenses was $71.3 million in Q3 2025, compared to $11.1 million in Q2 2025 and $19.8 million in Q1 2025.